Calquence capsules show safety in untreated CLL patients

NCT ID NCT05665374

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 25 times

Summary

This study tracked side effects of the drug Calquence (acalabrutinib) in 67 people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal was to see how often side effects like infections or low blood counts happen in real-world use. Participants took 100 mg capsules and were monitored for adverse reactions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKAEMIA (INCLUDING SMALL LYMPHOCYTIC LYMPHOMA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Aichi, Japan
Research Site

Chiba, Japan
Research Site

Fukuoka, Japan
Research Site

Hyōgo, Japan
Research Site

Kanagawa, Japan
Research Site

Kyoto, Japan
Research Site

Miyazaki, Japan
Research Site

Nagano, Japan
Research Site

Nara, Japan
Research Site

Okayama, Japan
Research Site

Osaka, Japan
Research Site

Saitama, Japan
Research Site

Shizuoka, Japan
Research Site

Tokyo, Japan
Research Site

Yamanashi, Japan

Conditions

Explore the condition pages connected to this study.

PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKAEMIA (INCLUDING SMALL LYMPHOCYTIC LYMPHOMA)